PeptiDream Inc. is a public (Tokyo Stock Exchange 1st Section 4587) biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System(PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics. PeptiDream aspires to be a world leader in drug discovery and development to address unmet medical needs and improve the quality of life of patients worldwide

PeptiDream is a biopharmaceutical company that employs its proprietary PDPS (Peptide Discovery Platform System) Technology, a revolutionary next-generation hit finding platform, for the discovery and development of constrained peptides, small molecule, and peptide-drug conjugate therapeutics.

Using the PDPS technology, PeptiDream works in close collaboration with its global and strategic/joint partners, or on its own internal target programs, to identify hit candidates and depending on the therapeutic area and intended route of administration.